About Nuvalent
Nuvalent is a publicly listed company based in Cambridge (United States) founded in 2017, and was acquired by GSK in June 2026. Therapeutic solutions for cancer, including NSCLC inhibitors, are developed. Nuvalent has raised $185 million across 2 funding rounds from investors including Fidelity Investments, Janus Henderson Investors and Driehaus. The company has 142 employees. Its chief executive, as recorded, is James Porter. Its website nuvalent.com draws about 28 thousand monthly visits. Nuvalent offers products and services including Zidesamtinib, Neladalkib, and NVL-330. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Diversified. Its legal entity is NUVALENT, INC. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Nuvalent was founded in 2017 and is based in Cambridge, United States. Oncology therapeutics are developed by the company, with emphasis on ROS1-selective inhibitors for non-small cell lung cancer and central nervous system metastasis. Drug candidates such as NUV-520 and NUV-655 are advanced to address lung cancer, breast cancer, and additional tumor types in clinical settings.
- Headquarters Cambridge, United States
- Employees 142
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website nuvalent.com
- Social LinkedIn X
- Acquired by GSK (Jun 2026)
- Legal Name Nuvalent, Inc.
- Net Profit-$260.76 M (USD)-106.59as on Dec 31, 2024
- EBITDA-$280.37 M (USD)-87.55as on Dec 31, 2024
- Total Equity Funding$185M (USD)
in 2 rounds
- Latest Funding Round$135M (USD), Series B
May 2021
- InvestorsFidelity Investments
& 12 more
- Employee Count142
- Acquired byGSK
(Jun 2026)
Products & Services of Nuvalent
Nuvalent offers a comprehensive portfolio of products and services, including Zidesamtinib, Neladalkib, and NVL-330.
Targets advanced ROS1-positive NSCLC in clinical trials.
Inhibits ALK-positive NSCLC for patient treatment.
Focuses on HER2-altered NSCLC in phase 1 studies.
Funding Insights of Nuvalent
Nuvalent has successfully raised a total of $185M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $185M
- Total Rounds 2
- Last Round Series B — $135M
- First Round $50M
(Jan 2021)
- Investors Count 12
All 2 funding rounds of Nuvalent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $135M | Series B | – | Bain Capital Life Sciences | |
| Jan 2021 | $50M | Series A | – | Deerfield | – |
13 investors in total: 13 institutional.
Investors in Nuvalent
Nuvalent has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Janus Henderson Investors and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Venture capital fund focused on biotechnology startups | avorocapital.com | New York, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States |
Investor details for Nuvalent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nuvalent
70 people are tracked at Nuvalent (42 in leadership, 13 in board & advisors, 15 in team); the tracked headcount is 142.
| Name | Role | Group |
|---|---|---|
James Porter | CEO | Leadership |
Nicole A. Wits | Director, National Accounts | Strategic Engagement | Leadership |
Rebecca Hoffman | Senior Director, Human Resources Business Partner – Commercial & G&a | Leadership |
Chrisie Ding | Head Of Statistical Programming | Leadership |
Prabjyot Singh Sachdev | Associate Director Corporate Strategy | Leadership |
Kanan B. | Senior Medical Director | Leadership |
Chris Cooper | Senior Director, Chemical Development | Leadership |
Josh Bergren | Director Of Patient Marketing | Leadership |
Bill Pentz | Senior Director, Commercial Insights & Analytics | Leadership |
Wint Swe | Associate Director, Clinical Sciences | Leadership |
Joshua Horan | VP, Chemistry | Leadership |
Shannon Dauksis | Senior Director, Program Management | Leadership |
Misty Braun | Senior Regional Business Director, Southeast | Leadership |
Viola Zhu | Medical Director | Leadership |
Matthew Metivier | VP, Human Resources | Leadership |
Anupong Tangpeerachaikul | Director | Leadership |
Junwu Shen | Vice President, Biostatistics And Programming | Leadership |
Chad Nagel | Senior Director, Revenue Accounting | Leadership |
Alex Balcom | CFO | Leadership |
Baudouin Gerard | Director, Chemistry | Leadership |
50 more people are available in the full profile.
Complete people profiles for Nuvalent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nuvalent
Nuvalent is a publicly listed company on the NASDAQ with ticker symbol NUVL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Jul 2021
- Listed onNASDAQ: NUVL
- Listed entityNuvalent, Inc.
- Exchange sectorHealth technology
- ISINUS6707031075
- Share price$105.28 (+2.81% on the day) · 2026-05-11
- Market capitalisation$8.31B
- EPS (diluted, trailing year)$-6.06
- Volume (last session)579,883
- Analyst consensusStrong buy
Financials of Nuvalent
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$260.8M | -$280.4M | |
| 2023 | -$126.2M | -$149.5M | |
| 2022 | -$81.8M | -$86.1M | |
| 2021 | -$46.3M | -$45.8M |
Detailed financial statements for Nuvalent
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Nuvalent
5 dated milestones of Nuvalent across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Nuvalent is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series B, of $135.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by GSK.
Competitors of Nuvalent
Nuvalent has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Nuvalent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nuvalent
The website of Nuvalent (nuvalent.com) receives about 28.1K visits a month and ranks #1,747,173 among all websites worldwide, #2,372 in Biotechnology and Pharmaceuticals.
- Monthly visits28.1K
▲ 120.2% vs previous month
- Unique visitors4.9K
per month
- Global rank#1,747,173
among all websites
- Category rank#2,372
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit2.5
- Average visit1 min 21 sec
- DevicesDesktop 56% · Mobile 44%
Websites whose visitors overlap most with Nuvalent. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
life-sciences-usa.com | life-sciences-usa.com | 100% | #1,482,544 | – | |
| google.com | 48% | 85.8B | #1 | View details | |
| 5amventures.com | 48% | #2,774,398 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Nuvalent (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuvalent
Complete news archive for Nuvalent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuvalent
Nuvalent was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Nuvalent is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
James Porter is the CEO of Nuvalent, as recorded in our data.
Nuvalent is a funded company, having raised a total of $185M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Jan 2021.
Nuvalent has 142 employees.
Nuvalent was founded in 2017 and is based in Cambridge, United States. Oncology therapeutics are developed by the company, with emphasis on ROS1-selective inhibitors for non-small cell lung cancer and central nervous system metastasis. Drug candidates such as NUV-520 and NUV-655 are advanced to address lung cancer, breast cancer, and additional tumor types in clinical settings.
Nuvalent's top competitors include C4 Therapeutics, Erasca and MiRagen.
Nuvalent offers Zidesamtinib, Neladalkib, and NVL-330.
Yes, Nuvalent is publicly traded on NASDAQ under the ticker symbol NUVL.
Nuvalent has 13 investors. Key investors include Fidelity Investments, Janus Henderson Investors, Driehaus, GSK, and Deerfield.
Nuvalent operates through Nuvalent, Inc..
Yes. Nuvalent was acquired by GSK in June 2026.